Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.nbd.2018.11.026
DC FieldValue
dc.titleAssessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and alpha-lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?
dc.contributor.authorSharman, Matthew J
dc.contributor.authorGyengesi, Erika
dc.contributor.authorLiang, Huazheng
dc.contributor.authorChatterjee, Pratishtha
dc.contributor.authorKarl, Tim
dc.contributor.authorLi, Qiao-Xin
dc.contributor.authorWenk, Markus R
dc.contributor.authorHalliwell, Barry
dc.contributor.authorMartins, Ralph N
dc.contributor.authorMunch, Gerald
dc.date.accessioned2020-08-21T05:55:52Z
dc.date.available2020-08-21T05:55:52Z
dc.date.issued2019-04-01
dc.identifier.citationSharman, Matthew J, Gyengesi, Erika, Liang, Huazheng, Chatterjee, Pratishtha, Karl, Tim, Li, Qiao-Xin, Wenk, Markus R, Halliwell, Barry, Martins, Ralph N, Munch, Gerald (2019-04-01). Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and alpha-lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?. NEUROBIOLOGY OF DISEASE 124 : 505-519. ScholarBank@NUS Repository. https://doi.org/10.1016/j.nbd.2018.11.026
dc.identifier.issn09699961
dc.identifier.issn1095953X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/173270
dc.description.abstract© 2018 Increasingly, evidence is accumulating pointing at a protective role of a healthy diet at decreasing the risk of Alzheimer's disease. To test the effectiveness of nutritional components, the following food-derived compounds: curcumin alone (curcumin), curcumin combined with (−)epigallocatechin-3-gallate (EGCG), docosahexaenoic acid (DHA) and α-lipoic acid (ALA) (curcumin + EDA), or a combination of EGCG, DHA and ALA (EDA) were assessed in male Tg2576 transgenic mice on amyloid plaque load, amyloid levels (Aβ40/Aβ42, but not oligomers due to tissue limitations), microglial activation and memory using the contextual and cued fear conditioning test. The combination diet EDA, resulted in the strongest reduction of amyloid plaque load in both the cortical (p <.0001) and hippocampal (p <.0001) areas of the Tg2576 mouse brain, along with lower Aβ40/Aβ42 levels in the frontal cortex (p =.000129 and p =.000039, respectively) and Aβ42 levels in the temporal lobe (p =.000082). A curcumin only diet was shown to lower amyloid plaque load (p =.028), but when combined with EGCG, DHA and ALA did not result in further decreases in amyloid plaque load. The EDA combination group showed the most prominent decrease in microglial activation (number of microglia around plaques: p <.05 and p <.0001, respectively, for the cortex and hippocampus). Analysing the hippocampal associated contextual fear conditioning revealed that both the curcumin+EDA (p <.0001) and EDA groups (p =.001) spent increased time on freezing compared to the control group. In addition, the curcumin+EDA group showed a significant increase in time spent freezing compared with the curcumin only group. In the amygdala associated cued test, all mice demonstrated the ability to associate the conditioned stimulus with the unconditioned stimulus as evidenced by a significant increase in freezing behaviour in response to the presentation of the cue (p <.0001). Post-hoc analysis showed that only curcumin+EDA (p <.0001) and EDA groups (p <.0001) developed a significant increase in freezing during the cue presentation. The results from this study show that the combination of EGCG, DHA and ALA (EDA) appeared to have the most potent anti-inflammatory and neuroprotective effect. Our results also demonstrate that interactions between nutraceutical products might result in counterproductive outcomes, highlighting the fact that manufacturers of nutraceuticals containing multiple compounds should be careful not to claim additive or synergistic effects of their combination products in vivo without having tested it in animal models and/or human clinical trials.
dc.language.isoen
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCE
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectNeurosciences
dc.subjectNeurosciences & Neurology
dc.subjectCurcumin
dc.subjectMicroglia
dc.subjectAmyloid plaque
dc.subjectInflammation
dc.subjectLipoic acid
dc.subjectGreen tea
dc.subjectFish oil
dc.subjectOXIDATIVE DAMAGE
dc.subjectPLAQUE LOAD
dc.subjectRAT MODEL
dc.subjectBETA
dc.subjectPATHOLOGY
dc.subjectTG2576
dc.subjectPROTEIN
dc.subjectPLASMA
dc.subjectBRAIN
dc.subjectEGCG
dc.typeArticle
dc.date.updated2020-06-17T04:09:51Z
dc.contributor.departmentBIOCHEMISTRY
dc.description.doi10.1016/j.nbd.2018.11.026
dc.description.sourcetitleNEUROBIOLOGY OF DISEASE
dc.description.volume124
dc.description.page505-519
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
23. Assessment of diets containing curcumin, epigallocatechin-3-gallate.pdfPublished version3.23 MBAdobe PDF

CLOSED

None

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.